qFibrosis® for MASH and MASLD
Transforming Liver Fibrosis Assessment
qFibrosis® is an automated, quantitative technique to evaluate liver fibrosis in patients with Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-associated Steatohepatitis (MASH). It uses second harmonic generation/two-photon excitation fluorescence (SHG/TPEF) microscopy and artificial intelligence (AI) to analyze liver biopsy images and output values on a continuous scale for measurement of severity of fibrosis.
Quantification of over 180 Collagen Parameters
Developed with Experts
qFibrosis® was developed by HistoIndex in partnership with clinician key opinion leaders and trained, validated and tested extensively to confirm robust performance.
Using predictive models to correlate histological fibrosis staging systems and quantitative analysis of architectural, morphological and spatial distribution of collagen fibers, qFibrosis® consolidates these collagen parameters into a single quantitative index on a continuous scale.
Implementing AI-Assisted Evaluation in Practice
A New Era in Evaluation
qFibrosis® has shown excellent ability to quantify fibrosis accurately in clinical trials and to provide greater insights into treatment-induced histological changes. This makes qFibrosis® a state-of-the-art tool for assessing liver fibrosis in the biopsies of patients with MAFLD/MASH.
Improved Fibrosis Measurement
Provides quantitative and continuous measurement of fibrosis to capture subtle changes and better differentiates between intermediate fibrosis stages by traditional semiquantitative (categorical) staging systems
Abdurrachim, Desiree., et al. AASLD 2023.
Greater Sensitivity to Regression
Identifies fibrosis regression in patients post-treatment who were otherwise deemed as “unchanged” by semiquantitative and ordinal staging system
Naoumov, Nikolai V., et al. Journal of Hepatology 77.5 (2022): 1399-1409.
Zonal Analysis
Allows localized assessment of fibrosis changes in portal tracts, periportal, transitional, pericentral and central veins of the liver lobule, which correlate better to disease states than overall collagen measurement of the entire biopsy
Multi-parametric Approach
Analyzes hundreds of collagen-related architectural and morphological patterns including fiber count, length, width, cross linkages and the co-localization of these collagen patterns with the activities of MAFLD in their respective spatial zones in order to provide richness beyond histopathological categorical fibrosis staging
Future-Proofing Pathology
We are always innovating to extract deeper insights from tissue complexity and drive transformative outcomes for our partners. If you would like to explore how a digital pathology platform can improve your findings, let us know.
qFibrosis® FAQs
qFibrosis® is a proprietary, automated quantitative fibrosis assessment technology developed by HistoIndex that uses Second Harmonic Generation (SHG) and Two-Photon Excitation Fluorescence (TPEF) microscopy combined with AI to objectively measure liver fibrosis on a continuous scale rather than relying on subjective categorical scores.
qFibrosis® analyzes high-resolution images of unstained liver biopsy tissue captured by SHG/TPEF microscopy and applies machine learning to evaluate over 180 collagen architectural parameters, such as fiber morphology, spatial distribution, and linkage, producing a single continuous index representing fibrosis severity.
Unlike conventional staging systems that categorize fibrosis into broad stages (F0–F4), qFibrosis® delivers continuous, quantitative measurements capturing subtle changes in collagen structure and disease progression that may be missed by semiquantitative approaches. This improves sensitivity, especially for intermediate fibrosis stages.
qFibrosis® is commonly used for assessing liver fibrosis in conditions such as Metabolic Dysfunction-Associated Steatohepatitis (MASH)/MASLD and Non-Alcoholic Fatty Liver Disease (NAFLD), providing deeper insights into disease severity and treatment effects.
Yes, research indicates that quantifying morphological and spatial collagen features with AI-based analysis can reveal subtle patterns of fibrosis change (including regression) that may not be captured by conventional histology scoring systems.
AI algorithms in qFibrosis® automate the identification and quantification of collagen features in biopsy images, reducing variability from manual interpretation and enabling consistent, high-precision fibrosis measurement across samples.
qFibrosis® was developed in collaboration with clinical and pathology experts and validated across extensive datasets to ensure robust performance, correlating its continuous index with established histological staging systems while enhancing reproducibility and sensitivity.
Yes, qFibrosis® supports zonal analysis (assessing fibrosis around portal tracts, periportal regions, and central veins) to correlate specific spatial changes in collagen with disease mechanisms and responses more accurately than overall biopsy averages.